Breakthrough Prostate Cancer Treatment Discovered: Is This The Miracle Patients Have Been Waiting For?

The battle against prostate cancer, a disease that affects a significant number of Australian men, particularly those over the age of 60, has been long and arduous. However, a ray of hope has emerged from the corridors of Sydney's St Vincent's Hospital, where a groundbreaking drug trial is offering new hope to patients with advanced prostate cancer.


The trial, which is a beacon of light for many, has already changed the life of 71-year-old yachtsman Rob Lewis. Diagnosed with metastatic prostate cancer, a condition where the cancer has spread to other parts of the body, Lewis was facing a grim prognosis. The pain that he initially attributed to a racing injury turned out to be a life-altering diagnosis. But thanks to this innovative drug trial, Lewis has experienced a remarkable turnaround. After just three months of treatment, his cancer became 'undetectable,' a term that brings immense relief and joy to anyone familiar with the disease.


1719978435454.png
New drug trial at St Vincent's Hospital offered hope to advanced prostate cancer patients. Credit: 9News / YouTube


The trial, led by Professor Louise Emmett and funded by Movember and the federal government, involved 162 men who were battling advanced stages of prostate cancer. The participants were divided into two groups: one received the drug enzalutamide alone, while the other was treated with a combination of enzalutamide and a novel radiation treatment known as Lutetium-PSMA-617.


The results have been nothing short of extraordinary. Patients on the combination therapy showed an improved response to the treatment and, importantly, experienced fewer side effects. This is a significant development, as the quality of life during cancer treatment is a critical concern for patients and their families. Dr. Megan Crumbaker, an oncologist involved in the trial, highlighted the dual benefits of the treatment, noting its effectiveness and the minimal side effects, which she described as 'the whole shebang.'

The interim findings of this trial have been published in The Lancet Oncology, and they paint a picture of a potential future where prostate cancer could be transformed from a lethal disease with severe symptoms to a chronic condition that patients can manage while continuing to enjoy their lives.

However, there's a catch. The treatment, particularly the Lutetium-PSMA-617 component, comes with a hefty price tag. Currently, there is no funding for this treatment in Australia, which means it's out of reach for many who could benefit from it. Both Emmett and Lewis are advocating for change, hoping to see Lutetium-PSMA-617 become more accessible to patients across the country. 'It should be available to everybody. It's just a game changer,' Lewis passionately stated.


For Lewis, the drug trial has given him a new lease on life. The appreciation for the simple things, the ability to spend precious time with loved ones, and the chance to look after his granddaughter a few days a week are gifts that he attributes to the success of the treatment.

This trial is a testament to the power of medical research and the importance of funding such initiatives. It also serves as a reminder to our readers that participation in clinical trials can sometimes offer access to cutting-edge treatments that are not yet widely available.

As we continue to follow the progress of this trial and the push for funding, we invite our readers to share their thoughts and experiences. Have you or a loved one been affected by prostate cancer? What are your hopes for the future of treatment? Your stories are important, and by sharing them, we can foster a community of support and information.


For those interested in learning more about this trial or seeking support for prostate cancer, there are resources available, such as Prostate Cancer Foundation of Australia (PCFA), which offers guidance and community support for those affected by the disease.
Key Takeaways
  • A drug trial at St Vincent's Hospital in Sydney is offering new hope to patients with advanced prostate cancer.
  • Rob Lewis, a participant in the trial, saw his metastatic prostate cancer become 'undetectable' after just three months with minimal side effects.
  • The trial, led by Professor Louise Emmett and funded by Movember and the federal government, combines enzalutamide with radiation treatment Lutetium-PSMA-617.
  • Interim findings show that the combination therapy shows improved response and fewer side effects, with hopes that Lutetium-PSMA-617 becomes more widely available and funded in Australia.
The journey to conquer prostate cancer is far from over, but with each scientific advancement, we move closer to a world where this disease no longer poses the threat it once did. For now, we celebrate the successes and continue to support the tireless efforts of researchers, clinicians, and patients who are on the front lines of this fight.
 
Sponsored
That is excellent news as I understand that 1 in 6 men in Australia end up with prostate cancer as they age. One might hope that that treatment becomes funded so that it is affordable by all.
 
My husband was diagnosed with prostrate caancer in 2016 but after 8 weeks radiotherapy in early 2017 his PSA is now down to .01 after rising rapidly in early 2016 from 4.9 up to 12.5 by January when he started his radiation. His PSA came down slowly over the next 5 years to now .01 so we are very happy now .
 
  • Love
Reactions: BeautifulMousey
To all you men with early stage (Contained) prostate cancer, cryogenic surgery is the way to go. Eliminates the inevitable consequences of incontinence and impotence
 
  • Like
Reactions: BeautifulMousey
My husband was diagnosed with prostrate caancer in 2016 but after 8 weeks radiotherapy in early 2017 his PSA is now down to .01 after rising rapidly in early 2016 from 4.9 up to 12.5 by January when he started his radiation. His PSA came down slowly over the next 5 years to now .01 so we are very happy now .
Darolutamide, approved for sale on the PBS last November, along with a separate 3-monthly drug injection can be effective in reducing the PSA level to below detection i.e 0.01 quickly. It is also guaranteed to ruin one's sex life as it assists in knocking testosterone on the head. Side effects may include hot flushes.

Lutetium is one of those elements of which there would be assorted radioactive isotopes. I have no idea what is PMSA-617 but perhaps that is a vehicle that carries the radioactive Lutetium to the appropriate places in the bone so as to knock the cancer on its head. That is just a complete guess on my part, so don't quote me. Lutetium-Hafnium radioactive dating is used to date the ages of certain rock-forming minerals and thus obtain the age of the rocks containing those minerals.
 
  • Like
Reactions: BeautifulMousey

Join the conversation

News, deals, games, and bargains for Aussies over 60. From everyday expenses like groceries and eating out, to electronics, fashion and travel, the club is all about helping you make your money go further.

Seniors Discount Club

The SDC searches for the best deals, discounts, and bargains for Aussies over 60. From everyday expenses like groceries and eating out, to electronics, fashion and travel, the club is all about helping you make your money go further.
  1. New members
  2. Jokes & fun
  3. Photography
  4. Nostalgia / Yesterday's Australia
  5. Food and Lifestyle
  6. Money Saving Hacks
  7. Offtopic / Everything else

Latest Articles

  • We believe that retirement should be a time to relax and enjoy life, not worry about money. That's why we're here to help our members make the most of their retirement years. If you're over 60 and looking for ways to save money, connect with others, and have a laugh, we’d love to have you aboard.
  • Advertise with us

User Menu

Enjoyed Reading our Story?

  • Share this forum to your loved ones.
Change Weather Postcode×
Change Petrol Postcode×